Oculis (OCS) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Oculis (OCS) over the past year, gaining 90.6% versus a loss of 56.4%. Over five years, PBYI leads with a +64.8% price change compared with -11.8% for OCS. Puma Biotechnology is the larger company by market cap ($530.7 million vs $513.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCS | PBYI |
|---|---|---|
| Share price | $8.33 | $10.28 |
| Market cap | $513.03M | $530.65M |
| 1-day change | -3.81% | +3.11% |
| YTD return | -56.63% | +67.56% |
| 1-year return | -56.42% | +90.63% |
| 5-year return | -11.81% | +64.79% |
| P/E ratio (TTM) | — | 20.16 |
| Forward P/E | — | 29.37 |
| EPS (TTM) | $-1.74 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.48 | $10.35 |
| 52-week low | $8.30 | $4.58 |
| Distance from 52-week high | -75.84% | -0.68% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +338.06% | — |
| Average volume | 257.00K | 320.69K |
| Shares outstanding | 61.59M | 51.62M |
| Employees | 60 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed OCS by 147.0 percentage points over the past year.
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
OCS vs PBYI FAQ
Which is bigger, Oculis or Puma Biotechnology?
Puma Biotechnology (PBYI) is larger, with a market capitalization of $530.65M compared with $513.03M for Oculis (OCS).
Which stock has performed better over the past year, OCS or PBYI?
PBYI returned +90.63% over the past 12 months, compared with -56.42% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Oculis and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.